Cargando…

Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”

Detalles Bibliográficos
Autores principales:	Murakami, Eisuke, Bilello, John, Li, Ruidong, Li, Li, Porter, Danielle, Humeniuk, Rita, Mackman, Richard, Cihlar, Tomas, Osinusi, Anu, Feng, Joy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448133/ https://www.ncbi.nlm.nih.gov/pubmed/34370585 http://dx.doi.org/10.1128/AAC.01394-21

Ejemplares similares

Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021)

Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020)

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
por: Humeniuk, Rita, et al.
Publicado: (2021)

Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver
por: Yan, Victoria C., et al.
Publicado: (2021)

Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
por: Xu, Yili, et al.
Publicado: (2021)

Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection
por: Vermillion, Meghan S., et al.
Publicado: (2021)

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
por: Schäfer, Alexandra, et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells
por: Li, Ruidong, et al.
Publicado: (2021)

Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
por: Schäfer, Alexandra, et al.
Publicado: (2022)

Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir
por: Gordon, Calvin J., et al.
Publicado: (2021)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets
por: Cox, Robert M., et al.
Publicado: (2021)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
por: Martin, Ross, et al.
Publicado: (2021)

Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2022)

Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
por: Chokkalingam, Anand P., et al.
Publicado: (2022)

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
por: Tchesnokov, Egor P., et al.
Publicado: (2019)

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
por: Agostini, Maria L., et al.
Publicado: (2018)

Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques
por: Peart Akindele, Nadine A., et al.
Publicado: (2023)

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
por: Pruijssers, Andrea J., et al.
Publicado: (2020)

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting
por: Pan, David Z., et al.
Publicado: (2023)

Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro
por: Radoshitzky, Sheli R., et al.
Publicado: (2023)

Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2
por: Mackman, Richard L.
Publicado: (2022)

Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus
por: Warren, Travis K., et al.
Publicado: (2021)

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
por: Sheahan, Timothy P., et al.
Publicado: (2020)

Yan Zoritchak
por: Zoritchak, Yan
Publicado: (2003)

538. Clinical Evaluation of Drug-drug Interactions with Remdesivir
por: Peng, Chi-Chi, et al.
Publicado: (2023)

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
por: Gordon, Calvin J., et al.
Publicado: (2020)

Ablation of Kcnj10 expression in retinal explants revealed pivotal roles for Kcnj10 in the proliferation and development of Müller glia
por: Arai, Eisuke, et al.
Publicado: (2015)

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
por: Stevens, Laura J., et al.
Publicado: (2022)

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
por: Hill, Joshua A, et al.
Publicado: (2021)

545. Remdesivir And Obeldesivir Retain Potent Activity Against SARS-CoV-2 Omicron Variants
por: Rodriguez, Lauren, et al.
Publicado: (2023)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

Yan el cimarrón
por: Barroso, Edwigis
Publicado: (1984)

Drell-Yan Workshop
por: Fermi National Accelerator Laboratory. Batavia
Publicado: (1983)

The Drell-Yan process
por: Kenyon, Ian Richard
Publicado: (1982)

Drell-Yan processes
por: Freudenreich, Klaus
Publicado: (1984)

Profile of Nieng Yan
por: Ravindran, Sandeep
Publicado: (2022)

Is the Personal Identity Debate a “Threat” to Neurosurgical Patients? A Reply to Müller et al.
por: Nyholm, Sven
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vkvm0aua3drfgnecl71gbdr04e